Benefits and Limitations of Real‐World Patient‐Reported Toxicity Symptom Monitoring for Guidelines and Care, as Perceived by Patients, Clinicians, and Guideline Developers
The benefits and limitations of adopting patient-reported real-world toxicity symptom monitoring need to be leveraged and addressed to ensure maximum value and uptake. Guideline developers viewed aggregated data as beneficial. The identified knowledge gaps provide concrete points of action for CML guideline development.
Authors
- André Dekker (ORCID: https://orcid.org/0000-0002-0422-7996)
- Yolba Smit (ORCID: https://orcid.org/0000-0003-4799-4981)
- Jeroen J. W. M. Janssen (ORCID: https://orcid.org/0000-0001-9567-1955)
- Eduardus F. M. Posthuma (ORCID: https://orcid.org/0000-0002-0882-2346)
- Alan Currie (ORCID: https://orcid.org/0000-0001-5617-4868)
- Rosella Hermens (ORCID: https://orcid.org/0000-0001-7624-7120)
- L. Verweij
- Nicole Blijlevens
Institutions
- Radboud University Nijmegen (NL)
- Maastricht University Medical Centre (NL)
- Radboud University Medical Center (NL)
- Reinier de Graaf Hospital (NL)
- Maastro Clinic (NL)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/cam4.70880
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- AbbVie
- ZonMw
- Janssen Pharmaceuticals